Abstract
The patients experiencing an acute coronary event are exposed to increased risk of thromboembolic events. That risk becomes substantially greater when AF fibrillation and heart failure are present as well. Dual antiplatelet therapy remains the gold standard in the treatment of patients with ACS. The combination of an oral anticoagulant agent with dual antiplatelet therapy is proven to be more effective in prevention of further antithrombotic events but is followed by increased risks of clinically significant bleeding thus it is not suggested in the treatment of ACS. However, it has been proven beneficial in patients with AF who present with an acute coronary episode. NOACs have proved to be at least as effective as vitamin K antagonists in protecting patients with atrial fibrillation from thromboembolic events without increased risk of major bleeding. However, only data on the effectiveness of NOACS in patients with ACS and AF have been quite contradictory. Even more, the data on the effect of NOACS in patients with concomitant HF and AF who present with an acute coronary event is almost lacking from current bibliography. In this review, we attempt to describe the available data of the use of NOACS in patients with AF and HF who experience an ACS and to address the need for further studies in this area.
Keywords: Acute coronary syndromes, atrial fibrillation and heart failure, novel oral anticoagulants.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Acute Coronary Syndromes in Patients with Atrial Fibrillation and Heart Failure. Could Novel Oral Anticoagulants be the Solution of the Optimal Antithrombotic Therapy Puzzle?
Volume: 12 Issue: 1
Author(s): Maria Boutsikou, Chrysafios Girasis, Emmanouil Petrou and Gregory Pavlides
Affiliation:
Keywords: Acute coronary syndromes, atrial fibrillation and heart failure, novel oral anticoagulants.
Abstract: The patients experiencing an acute coronary event are exposed to increased risk of thromboembolic events. That risk becomes substantially greater when AF fibrillation and heart failure are present as well. Dual antiplatelet therapy remains the gold standard in the treatment of patients with ACS. The combination of an oral anticoagulant agent with dual antiplatelet therapy is proven to be more effective in prevention of further antithrombotic events but is followed by increased risks of clinically significant bleeding thus it is not suggested in the treatment of ACS. However, it has been proven beneficial in patients with AF who present with an acute coronary episode. NOACs have proved to be at least as effective as vitamin K antagonists in protecting patients with atrial fibrillation from thromboembolic events without increased risk of major bleeding. However, only data on the effectiveness of NOACS in patients with ACS and AF have been quite contradictory. Even more, the data on the effect of NOACS in patients with concomitant HF and AF who present with an acute coronary event is almost lacking from current bibliography. In this review, we attempt to describe the available data of the use of NOACS in patients with AF and HF who experience an ACS and to address the need for further studies in this area.
Export Options
About this article
Cite this article as:
Boutsikou Maria, Girasis Chrysafios, Petrou Emmanouil and Pavlides Gregory, Acute Coronary Syndromes in Patients with Atrial Fibrillation and Heart Failure. Could Novel Oral Anticoagulants be the Solution of the Optimal Antithrombotic Therapy Puzzle?, Cardiovascular & Hematological Agents in Medicinal Chemistry 2014; 12 (1) . https://dx.doi.org/10.2174/1871525712666141010151155
DOI https://dx.doi.org/10.2174/1871525712666141010151155 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
PDE-5 Inhibitors: Clinical Points
Current Drug Targets Reduction of Sympathetic Hyperactivity by Agents that Inhibit the Renin Angiotensin Aldosterone System
Current Hypertension Reviews Current Indications for Infective Endocarditis Antibiotic Prophylaxis
Infectious Disorders - Drug Targets The Influence of Fatty Acids on Metoprolol - Human Serum Albumin Interaction in Low Affinity Binding Sites: A Multifactorial NMR Approach
Protein & Peptide Letters Angiotensin Converting Enzyme 2 Activator (DIZE) Modulates Metabolic Profiles in Mice, Decreasing Lipogenesis
Protein & Peptide Letters Regulation of Endothelial Cell Death and Its Role in Angiogenesis and Vascular Regression
Current Neurovascular Research Targeting Bacterial RNA Polymerase σ70 for Development of Broadspectrum Antisense Antibacterials
Recent Patents on Anti-Infective Drug Discovery Cardio-Vascular Risks Associated with Clozapine Treatment
Current Psychiatry Reviews Mesenchymal Stem Cells Derived from Wharton's Jelly of the Umbilical Cord: Biological Properties and Emerging Clinical Applications
Current Stem Cell Research & Therapy Hematopoietic Colony Stimulating Factors in Cardiovascular and Pulmonary Remodeling: Promoters or Inhibitors?
Current Pharmaceutical Design Pleiotropic Effects of ARB in Metabolic Syndrome
Current Vascular Pharmacology Differentiation-Inducing Therapy for Solid Tumors
Current Pharmaceutical Design Drug-Induced QTc Interval Prolongation: A Multicenter Study to Detect Drugs and Clinical Factors Involved in Every Day Practice
Current Drug Safety Editorial Focus on Cardiovascular Disease, Diabetes and Vessel Fibrosis
Recent Patents on Cardiovascular Drug Discovery Novel Strategies to Delineate Matrix Metalloproteinase (MMP)-Substrate Relationships and Identify Targets to Block MMP Activity
Mini-Reviews in Medicinal Chemistry Cerebrolysin Attenuates Heat Shock Protein (HSP 72 KD) Expression in the Rat Spinal Cord Following Morphine Dependence and Withdrawal: Possible New Therapy for Pain Management
Current Neuropharmacology Membrane and Soluble Forms of Endoglin in Preeclampsia
Current Molecular Medicine Side Effects of AAS Abuse: An Overview
Mini-Reviews in Medicinal Chemistry Nitric Oxide and Teratogenesis: An Update
Current Pharmaceutical Design Modulation of Angiogenesis for Cancer Prevention: Strategies Based On Antioxidants and Copper Deficiency
Current Pharmaceutical Design